The latent inhibition model of schizophrenia: Further validation using the atypical neuroleptic, clozapine

Biological Psychiatry

Volumn 40, Issue 9, 1996, Pages 834-843

  Weiner, Ina ^a   Shadach, Eran ^a   Tarrasch, Ricardo ^a   Kidron, Rachel ^a   Feldon, Joram ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Clozapine; Latent inhibition; Rat; Schizophrenia

Indexed keywords

AMPHETAMINE; CLOZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONDITIONING; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT INHIBITION; MALE; MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SCHIZOPHRENIA;

EID: 0030298492     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00573-0     Document Type: Article

References (66)

1. Barbee JG, Mancuso D, Freed CR, et al (1992): Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 149:506-510.
2. Baruch I, Hemsley D, Gray JA (1988): Differential performance of acute and chronic schizophrenics in a latent inhibition task. J Nerv Ment Dis 176:598-606.
3. Brier A, Buchanan RW, Kirkpatrick B, et al (1994): Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:20-26.
4. Bruhwyler J, Chleide E, Mercier M (1990): Clozapine - An atypical neuroleptic. Neurosci Biobehav Rev 14:357-363.
5. Carpenter WT Jr, Heinrichs DW, Alphs LD (1985): Treatment of negative symptoms. Schizophr Bull 11:440-452.
6. Carpenter WT Jr, Heinrichs DW, Wagman AMI (1988): Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 145:578-583.
7. Cassaday HJ, Hodges H, Gray JA (1993): The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat. J Psychopharmacol 77:63-77.
8. Chen J, Paredes W, Gardner EL (1992): Serotonin denervation enhances responsiveness of presynaptic dopamine efflux to acute clozapine in nucleus accumbens but not in caudateputamen. Brain Res 582:173-179.
9. Chiodo LA, Bunney SB (1985): Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J Neurosci 5:2539-2544.
10. Christison GW, Atwater GE, Dunn LA, Kilts CD (1988): Haloperidol enhancement of latent inhibition: Relation to therapeutic action? Biol Psychiatry 23:746-749.
11. Coward DM, Imperato A, Urwyler S, White TG (1989): Biochemical and behavioural properties of clozapine. Psychopharmacology 99:S6-S12.
12. 2/1C antagonist, and negative symptoms in schizophrenia: A placebo-controlled double-blind trial. Br J Psychiatry 163:451-455.
13. Dunn LA, Atwater GE, Kilts CD (1993): Effects of antipsychotic drugs on latent inhibition - Sensitivity and specificity of an animal behavioral model of clinical drug action. Psychopharmacology 112:315-323.
14. Farde L, Nordström AL (1992): PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry 160:30-33.
15. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99:S28-S31.
16. Feldon J, Weiner I (1988): Long-term attentional deficit in nonhandled males: Possible involvement of the dopaminergic system. Psychopharmacology 95:231-236.
17. Feldon J, Weiner I (1989): Abolition of the acquisition but not the expression of latent inhibition by chlordiazepoxide in rats. Pharmacol Biochem Behav 32:123-127.
18. Feldon J, Weiner I (1991): The latent inhibition model of schizophrenic attention disorder: Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli. Biol Psychiatry 29:635-646.
19. Gerlach J (1991): New antipsychotics: Classification, efficacy, and adverse effects. Schizophr Bull 17:289-309.
20. Gerlach J, Casey DE (1994): Drug treatment of schizophrenia: Myths and realities. Curr Opin Psychiatry 7:65-70.
21. Gray JA, Feldon J, Rawlins JNP, Hemsley DR, Smith AD (1991): The neuropsychology of schizophrenia. Behav Brain Sci 14:1-84.
22. Gray JA, Joseph MH, Hemsley DR, et al (1995): The role of mesolimbic dopaminergic and retrohippocampal afferents to the nucleus accumbens in latent inhibition: Implications for schizophrenia. Behav Brain Res 71:19-31.
23. Gray NS, Hemsley DR, Gray JA (1992a): Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol Psychiat Brain Res 1:83-89.
24. Gray NS, Pickering AD, Hemsley DR, Dawling S, Gray JA (1992b): Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology 107:425-430.
25. Jackson DM, Mohell N, Bengtsson A, Malmberg A (1993): What are atypical neuroleptics and how do they work? In Brunello N, Mendlewicz J, Racagni G (eds), New Generation of Antipsychotic Drugs: Novel Mechanisms of Action. Basel: Karger, pp 27-38.
26. Jann MW (1991): Clozapine. Pharmacotherapy 11:179-195.
27. Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic - A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
28. Kane JM, Freeman HL (1994): Towards more effective antipsychotic treatment. Br J Psychiatry 165:22-31.
29. Kane JM, Marder SR (1993): Psychopharmacologic treatment of schizophrenia. Schizophr Bull 19:287-302.
30. Kerwin RW (1994): The new atypical antipsychotics. Br J Psychiatry 164:141-148.
31. Killcross AS, Robbins TW (1993): Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology 110:479-489.
32. Killcross AS, Dickinson A, Robbins TW (1994): Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively-and appetitively-motivated paradigms - Evidence for dopamine-reinforcer interactions. Psychopharmacology 115: 196-205.
33. Leonard BE (1994): Serotonin receptors - Where are they going? Int Clin Psychopharmacol 9:7-17.
34. 18FESP. In Brunello N, Mendlewicz J, Racagni G (eds), New Generation of Antipsychotic Drugs: Novel Mechanisms of Action. Basel: Karger, pp 130-135.
35. Lubow RE (1973): Latent inhibition. Psychol Bull 79:398-407.
36. Lubow RE (1989): Latent Inhibition and Conditioned Attention Theory. Cambridge, England: Cambridge University Press.
37. Lubow RE, Gewirtz JC (1995): Latent inhibition in humans: Data, theory, and implications for schizophrenia. Psychol Bull 117:87-103.
38. Lubow RE, Weiner I, Schnur P (1981): Conditioned attention theory. In Bower GH (ed), The Psychology of Learning and Motivation. New York: Academic Press, vol 15, pp 1-49.
39. Mackintosh NJ (1975): A theory of attention: Variations in the associability of stimuli with reinforcement. Psychol Rev 82:276-298.
40. Mackintosh NJ (1983): Conditioning and Associative Learning. New York: Oxford University Press.
41. Meltzer HY (1989): Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27.
42. Meltzer HY (1991): The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287.
43. Meltzer HY, Bastani B, Ramirez L, Matsubara S (1989a): Clozapine - New research on efficacy and mechanism of action. Eur Arch Psychiatr Neurol Sci 238:332-339.
44. Meltzer HY, Matsubara S, Lee JC (1989b): The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390-392.
45. Moore JW, Stickney KJ (1980): Formation of attentional-associative networks in real time: Role of the hippocampus and implications for conditioning. Physiol Psychology 8:207-217.
46. [3] antagonist, facilitates latent inhibition in the rat. Pharmacol Biochem Behav 42:519-522.
47. Mortimer AM (1994): Newer and older antipsychotics: A comparative review of appropriate use. CNS Drugs 2:381-396.
48. Nutt DJ (1990): Specific anatomy, non-specific drugs: The present state of schizophrenia. J Psychopharmacol 4:171-175.
49. Peters SL, Joseph MH (1993): Haloperidol potentiation of latent inhibition in rats: Evidence for a critical role at conditioning rather than pre-exposure. Behav Pharmacol 4:183-186.
50. 2 receptor blocker. Drug Develop Res 8:205-211.
51. Schmajuk NA, Moore JW (1985): Real-time attentional models for classical conditioning and the hippocampus. Physiol Psychol 13:278-290.
52. Seeman P (1992): Dopamine receptor sequences - Therapeutic levels of neuroleptics occupy D2-receptors, clozapine occupies D4. Neuropsychopharmacology 7:261-284.
53. Solomon PR, Crider A, Winkelman JW, Turi A, Kamer RM, Kaplan LJ (1981): Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity: Relationship to schizophrenic attention disorder. Biol Psychiatry 16:519-537.
54. Tandon R, Kane JM (1993): Neuropharmacologic basis for clozapine's unique profile. Arch Gen Psychiatry 50:158-159.
55. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M (1993): Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiat Res 27:341-347.
56. van Tol HH, Bunzow JR, Guan HC, et al (1991): Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614.
57. Warburton EC, Joseph MH, Feldon J, Weiner I, Gray JA (1994): Antagonism of amphetamine-induced disruption of LI in rats by haloperidol and ondansetron: Implications for a possible antipsychotic action of ondansetron. Psychopharmacology 114:657-664.
58. Weiner I (1990): Neural substrates of latent inhibition: The switching model. Psychol Bull 108:442-461.
59. Weiner I, Feldon J (1987): Facilitation of latent inhibition by haloperidol. Psychopharmacology 91:248-253.
60. Weiner I, Feldon J (1994); The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action: Comment on Dunn, Atwater and Kilts (Psychopharmacology, 1993, 112:315-323). Psychopharmacology 116: 379-380.
61. Weiner I, Lubow RE, Feldon J (1981): Chronic amphetamine and latent inhibition. Behav Brain Res 2:285-286.
62. Weiner I, Lubow RE, Feldon J (1984): Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology 83:194-199.
63. Weiner I, Feldon J, Katz Y (1987): Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol Biochem Behav 26:241-246.
64. Weiner I, Lubow RE, Feldon J (1988): Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol Biochem Behav 30:871-878.
65. Weiner I, Kidron R, Tarrasch R, Arnt J, Feldon J (1994): The effects of the new antipsychotic, sertindole, on latent inhibition in rats. Behav Pharmacol 5:119-124.
66. Wiley JL, Compton AD, Porter JH (1993): Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 45:263-267.